A Multicenter, Randomized, Double Blind, Placebo Controlled, Proof of Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Weekly Subcutaneous MLN1202, in Improving Diabetic Nephropathy in Subjects With Macroalbuminuria

Trial Profile

A Multicenter, Randomized, Double Blind, Placebo Controlled, Proof of Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Weekly Subcutaneous MLN1202, in Improving Diabetic Nephropathy in Subjects With Macroalbuminuria

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Plozalizumab (Primary)
  • Indications Diabetic nephropathies
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 22 Sep 2017 Planned End Date changed from 1 Aug 2017 to 17 Nov 2015.
    • 22 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 17 Nov 2015.
    • 22 Sep 2017 Planned initiation date changed from 1 Apr 2016 to 20 May 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top